Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NantWorks, LLC
The latest oncology development news and highlights from our US FDA Performance Tracker.
While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.
Cancer drug-developer Black Diamond emerges from stealth mode with Series A and closes Series B in the same month, while aging-focused Juvenescence closes its initial tranche and looks complete Series B by the end of the quarter.
Celgene settles Abraxane patent litigation and inter partes review with Teva's Actavis, allowing a generic to enter the market on March 31, 2022 – about four years before the drug's key patents expire.
- In Vitro Diagnostics
- Monitoring Equipment & Devices
- Other Names / Subsidiaries
- Altor BioScience Corporation
- Altor BioScience, LLC
- IgDraSol, Inc.
- ImmunityBio, Inc.
- NantCell, Inc.